Between the first and second quarters of 2021, mentions of industrial automation in the archives of companies in the pharmaceutical sector fell by 34%.
In total, the frequency of industrial automation-related rulings between July 2020 and June 2021 was 27% lower than in 2016 when GlobalData, from which our data for this article is taken, first began tracking the key issues raised in corporate documents.
When pharmaceutical companies publish annual and quarterly reports, ESG reports and other documents, GlobalData analyzes the text and identifies individual sentences that refer to the disruptive forces that companies will face in the coming years. Industrial automation is one such topic: Companies that excel and invest in these areas are believed to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.
To assess whether industrial automation is more present in the summaries and strategies of pharmaceutical companies, two measures were calculated. First, we looked at the percentage of companies that cited industrial automation in their archives at least once in the last twelve months: this was 62% compared to 51% in 2016. Secondly, we calculated the percentage of total judgments analyzed that referred to automation.
Among the 50 largest employers of the pharmaceutical industry, Lonza Group Ltd was the company that made the most reference to industrial automation between July 2020 and June 2021. GlobalData has identified seven judgments related to industrial automation in the documents of the Swiss company : 0.3% of all sentences. Cipla Ltd mentioned industrial automation in second place: the issue was also mentioned in 0.3% of the judgments in the company’s files. Other major employers with high industrial automation mentions included AstraZeneca Plc, Novartis AG, and GlaxoSmithKline Plc.
Of all the pharmaceutical companies, the dossier released in the second quarter of 2021 that showed the greatest focus on industrial automation came from Pharming Group NV. Of the 2,748 judgments in the document, 11 (0.4%) referred to industrial automation.
This analysis provides a rough indication of which companies are focusing on industrial automation and how important the issue is within the pharmaceutical industry, but it also has limitations and should be interpreted carefully. For example, a company that mentions industrial automation more regularly is not necessarily proof that they are using new techniques or prioritizing the problem, nor does it indicate whether the company’s initiatives in industrial automation have been a success or a failure.
In the last quarter, pharmaceutical companies based in Western Europe were more likely to cite industrial automation with 0.11% convictions in corporate documents referring to the matter. By contrast, Canadian-based companies only mentioned industrial automation in 0.01% of the sentences.